CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1601-1607

  Miyazaki, K ^a   Yamaguchi, M ^a   Suzuki, R ^b   Kobayashi, Y ^c   Maeshima, A M ^c   Niitsu, N ^d   Ennishi, D ^e   Tamaru, J I ^f   Ishizawa, K ^g   Kashimura, M ^h   Kagami, Y ⁱ   Sunami, K ^j   Yamane, H ^k   Nishikori, M ^l   Kosugi, H ^m   Yujiri, T ⁿ   Hyo, R ^b   Katayama, N ^a   Kinoshita, T ^b   Nakamura, S ^b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g TOHOKU UNIVERSITY HOSPITAL   (Japan)

^h Matsudo City Hospital   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^k Sumitomo Besshi Hospital Cancer Center   (Japan)

^l KYOTO UNIVERSITY   (Japan)

^m OGAKI MUNICIPAL HOSPITAL   (Japan)

ⁿ YAMAGUCHI UNIVERSITY   (Japan)

more..

Author keywords

CD5; Central nervous system; Diffuse large B cell lymphoma; Prognosis; Rituximab

Indexed keywords

CD5 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN RADIOGRAPHY; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 79959721309     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq627     Document Type: Article

References (24)

1. Swerdlow SH, Campo E, Harris NLAB show et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC 2008.
2. Ogawa S, Yamaguchi M, Oka K et al. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall urvival. Br J Haematol 2004; 125: 180-186.
3. Ennishi D, Takeuchi K, Yokoyama M et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-1926.
4. Maeshima AM, Taniguchi H, Nomoto J et al. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 2009; 131: 339-346.
5. Went P, Zimpfer A, Tzankov A, Dirnhofer S. CD5 expression in de novo diffuse large B-cell lymphomas. Ann Oncol 2009; 20: 789-790.
6. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
7. Yamaguchi M, Nakamura N, Suzuki R et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008; 3: 1195-1202.
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
9. Linderoth J, Jerkeman M, Cavallin-Stahl E et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Clin Cancer Res 2003; 9: 722-728.
10. Johnson NA, Boyle M, Bashashati A et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773-3780.
11. Hyo R, Tomita N, Takeuchi K et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol 2010; 28: 27-32.
12. Murase T, Yamaguchi M, Suzuki R et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic eterogeneity of CD5. Blood 2007; 109: 478-485.
13. Bernstein SH, Unger JM, Leblanc M et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the outhwest Oncology Group. J Clin Oncol 2009; 27: 114-119.
14. Boehme V, Schmitz N, Zeynalova S et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896-3902.
15. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13: 1099-1107.
16. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. nn Oncol 2004; 15: 129-133.
17. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin ymphoma. Blood 2003; 102: 4284-4289.
18. Ferreri AJ, Batchelor T, Zucca E et al. International Collaborative Group against Primary CNS Lymphomas. J Clin Oncol 2003; 21: 1649-1650.
19. Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS ymphoma. J Clin Oncol 2006; 24: 3865-3870.
20. Soussain C, Hoang-Xuan K, Taillandier L et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512-2518.
21. Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-157.
22. Villa D, Connors JM, Shenkier TN et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of ituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-1052.
23. Quijano S, Lopez A, Manuel Sancho J et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin ncol 2009; 27: 1462-1469.
24. Imai H, Shimada K, Shimada S et al. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma. Pathol Int 009; 59: 431-437.